Antiretroviral therapy (ART) is a conventional standard in the treatment of HIV.Unfortunately, patients need to take their drugs on a daily basis and it is hard to follow the routine throughout a lifelong battle like this.Researchers at Rockefeller University suggest that an aggregation of HIV antibodies may keep the virus under control for entire months, potentially unburdening patients from the necessity to take their drugs.
In the phase 1b trial, researchers combined two broadly neutralising antibodies (bNAbs) named 3BNC117 and 10-1074. They had been found in people whose organisms successfully combated HIV alone, not being helped by drugs.Those antibodies target proteins to the surface of HIV virus in order to make the body's immune system capable of finding and destroying the virus. The participants of this trial stopped taking their antiretroviral drugs and became subject to three infusions of the bNAns on a once-per-three-weeks basis.The treatment suppressed the activity of the virus for a median of 21 weeks (or 15 weeks after the last injection) in the case of 9 individuals.
"These two antibodies are not going to work for everyone," stated the co-leader of the studies, Marina Caskey. "But if we start to combine this therapy with other antibodies or with antiretroviral drugs, it could be effective in more people."This is likely to affect future research and provide a chance for the total discontinuation of conventional drugs that are taken on a daily basis.